Rhythm Pharmaceuticals, Inc. (RYTM)

Market Cap	5.76B
Revenue (ttm)	136.86M
Net Income (ttm)	-174.02M
Shares Out	65.68M
EPS (ttm)	-2.82
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	532,584
Open	87.82
Previous Close	87.82
Day's Range	86.86 - 89.25
52-Week Range	40.61 - 94.80
Beta	2.27
Analysts	Strong Buy
Price Target	89.77 (+2.29%)
Earnings Date	Aug 5, 2025

About RYTM

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company’s lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 de...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 5, 2017
• Employees: 283
• Stock Exchange: NASDAQ
• Ticker Symbol: RYTM
• Website: https://rhythmtx.com

Financial Performance

In 2024, Rhythm Pharmaceuticals's revenue was $130.13 million, an increase of 68.06% compared to the previous year's $77.43 million. Losses were -$264.57 million, 43.3% more than in 2023.

Analyst Summary

According to 13 analysts, the average rating for RYTM stock is "Strong Buy." The 12-month stock price target is $89.77, which is an increase of 2.29% from the latest price.

Price Target

$89.77

(2.29% upside)

Analyst Consensus: Strong Buy